Skip to main
TNDM
TNDM logo

TNDM Stock Forecast & Price Target

TNDM Analyst Ratings

Based on 30 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 30%
Sell 3%
Strong Sell 0%

Bulls say

Tandem Diabetes Care is positioned for significant future growth due to a robust product pipeline and strong market presence, evidenced by a 20.6% year-over-year revenue increase to $252.4 million, surpassing consensus expectations. The company anticipates 13-14% revenue growth in the coming year, fueled by warranty renewals, steady supply sales, and growth in new pump starts, indicating its potential as a double-digit revenue growth MedTech firm. Additionally, the recent FDA clearance for Type 2 diabetes products has effectively more than doubled Tandem's addressable market in the U.S., enhancing its growth prospects amid increasing customer satisfaction and retention rates.

Bears say

Tandem Diabetes Care has faced ongoing operating losses since its inception, raising concerns about its ability to achieve sustained profitability amidst a backdrop of uncertain market conditions. The company's recent revenue guidance for 2025 appears underwhelming, reflecting seasonal trends and potential disruptions, while its gross margins have fallen short of consensus expectations, further highlighting financial strain. Additionally, various downside risks, such as slower market expansion, increased competition, reimbursement challenges, and ineffective R&D, contribute to a negative outlook for the stock.

TNDM has been analyzed by 30 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 30% suggest Holding, 3% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tandem Diabetes Care (TNDM) Forecast

Analysts have given TNDM a Buy based on their latest research and market trends.

According to 30 analysts, TNDM has a Buy consensus rating as of Jul 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $44.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $44.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tandem Diabetes Care (TNDM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.